Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | NA |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Glucocorticoid | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Acute lymphoblastic leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, etc. |
| Sample | Human CCRF-CEM, Jurkat and CEM/C1 cells |
| Expression Pattern | up-regulated |
| Function Description | lncRNA HOXA-AS2 was highly expressed both in prednisone insensitive ALL cell lines and patient samples. Gain or loss-of-function assays revealed that HOXA-AS2 enhanced GC resistance via promoting cell proliferation and inhibiting cell apoptosis. Furthermore, we validated that HOXA-AS2 upregulated HOXA3, thereby activating EGFR/Ras/Raf/MEK/ERK signaling pathway. |
| Pubmed ID | 30551418 |
| Year | 2019 |
| Title | TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for Acute lymphoblastic leukemia | OMIM COSMIC |